Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.
about
Vaccine adjuvants: mode of actionRecognition of lipopolysaccharide pattern by TLR4 complexesToll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responsesRoles and relevance of mast cells in infection and vaccinationBeyond empiricism: informing vaccine development through innate immunity researchSystems biology applied to vaccine and immunotherapy developmentAnti-cancer vaccines - a one-hit wonder?Toll-like receptors in antiviral innate immunityCombining cationic liposomal delivery with MPL-TDM for cysteine protease cocktail vaccination against Leishmania donovani: evidence for antigen synergy and protectionImmunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in miceAge-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infantsOuter membrane vesicles displaying engineered glycotopes elicit protective antibodiesIdentification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.Identification of Adjuvantic Activity of Amphotericin B in a Novel, Multiplexed, Poly-TLR/NLR High-Throughput Screen.New adjuvanted vaccines in pregnancy: what is known about their safety?193 nm ultraviolet photodissociation mass spectrometry for the structural elucidation of lipid A compounds in complex mixturesIdentification of novel synthetic toll-like receptor 2 agonists by high throughput screening.Rationally Designed TLR4 Ligands for Vaccine Adjuvant DiscoveryChemical synthesis and proinflammatory responses of monophosphoryl lipid A adjuvant candidates.Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonistsCombinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Particles Synergistically Enhances Innate and Adaptive Immune Responses.TLR4 ligands lipopolysaccharide and monophosphoryl lipid a differentially regulate effector and memory CD8+ T Cell differentiation.Synthesis and evaluation of monophosphoryl lipid A derivatives as fully synthetic self-adjuvanting glycoconjugate cancer vaccine carriersDownregulation of PTP1B and TC-PTP phosphatases potentiate dendritic cell-based immunotherapy through IL-12/IFNγ signaling.Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal α-synucleinopathyDifferential induction of innate immune responses by synthetic lipid a derivativesMultiparameter telemetry as a sensitive screening method to detect vaccine reactogenicity in miceSynthetic Toll like receptor-4 (TLR-4) agonist peptides as a novel class of adjuvantsEducating CD4 T cells with vaccine adjuvants: lessons from lipopolysaccharide.Modulating the innate immune response by combinatorial engineering of endotoxinCombinatorial contextualization of peptidic epitopes for enhanced cellular immunity.TRIF is required for TLR4 mediated adjuvant effects on T cell clonal expansion.Inefficient TLR4/MD-2 heterotetramerization by monophosphoryl lipid AMucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in miceInfluence of lipid A acylation pattern on membrane permeability and innate immune stimulation.The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate.Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay.Kdo2 -lipid A: structural diversity and impact on immunopharmacology.Alkaline phosphatase protects lipopolysaccharide-induced early pregnancy defects in mice.MyD88-dependent SHIP1 regulates proinflammatory signaling pathways in dendritic cells after monophosphoryl lipid A stimulation of TLR4.
P2860
Q21131210-D932309E-33C7-4D3B-944A-355EA22BC6C4Q24622138-7397DE69-404C-4ACA-A1F5-ED9E6F21DFF8Q24624348-1E24237D-C6E6-4D8F-8EF4-4BA1EDC0ED60Q26777264-598188E4-2994-4AC5-8506-D7E06DFEA9A5Q26824573-CF3CD6A7-D53D-46F1-B1A9-3318132263F9Q26830374-15652085-1262-4C0A-A0C6-DF5175E16DCFQ26995164-6ECC692D-EA07-4900-9DB9-5E45DCE78881Q27011462-D4095F9E-7379-4A0C-A496-E21B84B94AC9Q27304818-F4A69394-6B7E-4382-A1F7-1D5565AB1F04Q28730052-4466F8BE-6B1F-41B6-B6E5-765D8BBFC283Q28741059-1D4FDAFF-C00A-46C6-827C-6695CE9A35E7Q28831290-FEF2606F-C9B7-4997-BEF0-E5B8DB0A853FQ30371303-A0FE8AB6-369C-470F-9947-7F3A239AB427Q30388683-9BDD5EF3-644F-4D02-87E4-97DBB017CA68Q30396657-0027D3AE-9D8C-4C34-B481-2E42582B4C7FQ30420470-0B8AA251-DC3A-453F-9250-AEC7027D490CQ33588328-077632B8-F955-4AB6-8748-34E4DD64A550Q33654530-F3A5A82B-45F9-499A-A5FE-F592CA434164Q33714195-8825B861-895E-45A8-9853-1713C4C31A3CQ33721641-3569ABD4-F9AB-41A4-9531-696185C0AF32Q33746872-9FBEEA91-DC1E-483C-91E5-73403F22BB4EQ33807405-941C0BF3-284C-4B84-A846-300486F9323BQ33819711-4DDCB744-7F64-4CCE-8D90-8C19AF2A60F3Q33839267-3DB997D5-0E3C-457C-8B51-FB5577F8BF85Q33868678-5368A62C-0889-4C4F-AF20-FDDABF8FCFCDQ34121591-F83B01EB-9E6C-4B2F-AA76-6C5BEFDEAAA2Q34140252-DC3B4D6C-06B7-4EA4-B877-A8EEB27FBDD5Q34170285-49F28652-0D3E-4988-8AAE-9F941B38E4C1Q34258820-8884845C-8B50-44E7-B90F-AB9EF197AAFCQ34321369-EBF7261B-54BE-4487-9AE0-FF4537D9CFFCQ34400527-DB52A7FA-34E1-45EB-95CB-73254D2A8125Q34607160-5D9D3B57-5345-44E1-A18A-BA5EAEB2F73FQ34701875-7A54D2F1-B2F4-4B65-A7CC-1A8D1D718FCAQ34722855-9BCEC626-4367-4D2C-A153-6476906306CCQ34996712-DD64BB44-75DA-4875-A5F3-DB1F94D6803DQ35191903-ACB9CEB6-F1AF-43C4-842A-44ACE75A183BQ35377667-BE2108B0-807B-4A39-AA15-333E09635634Q35468441-69C27AE2-EEC0-4F77-9E6B-727DAEB9DB07Q35536407-C574273C-8670-4D32-9FB5-11665CE3724EQ35644967-695F5F7D-5A82-4412-B121-55314D04E1E4
P2860
Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Putting endotoxin to work for ...... nd effective vaccine adjuvant.
@en
Putting endotoxin to work for ...... nd effective vaccine adjuvant.
@nl
type
label
Putting endotoxin to work for ...... nd effective vaccine adjuvant.
@en
Putting endotoxin to work for ...... nd effective vaccine adjuvant.
@nl
prefLabel
Putting endotoxin to work for ...... nd effective vaccine adjuvant.
@en
Putting endotoxin to work for ...... nd effective vaccine adjuvant.
@nl
P2860
P1476
Putting endotoxin to work for ...... nd effective vaccine adjuvant.
@en
P2093
C R Casella
T C Mitchell
P2860
P2888
P304
P356
10.1007/S00018-008-8228-6
P577
2008-10-01T00:00:00Z